Literature DB >> 20149269

Imaging the D3 receptor in humans in vivo using [11C](+)-PHNO positron emission tomography (PET).

Eugenii A Rabiner1, Marc Laruelle.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20149269     DOI： 10.1017/S1461145710000088

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN： 1461-1457            Impact factor:   5.176


× No keyword cloud information.
  11 in total

1.  Age-related changes in binding of the D2/3 receptor radioligand [(11)C](+)PHNO in healthy volunteers.

Authors:  David Matuskey; Patrick Worhunksy; Elizabeth Correa; Brian Pittman; Jean-Dominique Gallezot; Nabeel Nabulsi; Jim Ropchan; Venkatesh Sreeram; Rohit Gudepu; Edward Gaiser; Kelly Cosgrove; Yu-Shin Ding; Marc N Potenza; Yiyun Huang; Robert T Malison; Richard E Carson
Journal:  Neuroimage       Date:  2016-02-11       Impact factor: 6.556

2.  Expression of dopamine D2 and D3 receptors in the human retina revealed by positron emission tomography and targeted mass spectrometry.

Authors:  Fernando Caravaggio; Enzo Scifo; Etienne L Sibille; Sergio E Hernandez-Da Mota; Philip Gerretsen; Gary Remington; Ariel Graff-Guerrero
Journal:  Exp Eye Res       Date:  2018-06-05       Impact factor: 3.467

3.  Heightened D3 dopamine receptor levels in cocaine dependence and contributions to the addiction behavioral phenotype: a positron emission tomography study with [11C]-+-PHNO.

Authors:  Doris E Payer; Arian Behzadi; Stephen J Kish; Sylvain Houle; Alan A Wilson; Pablo M Rusjan; Junchao Tong; Peter Selby; Tony P George; Tina McCluskey; Isabelle Boileau
Journal:  Neuropsychopharmacology       Date:  2013-08-07       Impact factor: 7.853

Review 4.  Rationale in support of the use of selective dopamine D₃ receptor antagonists for the pharmacotherapeutic management of substance use disorders.

Authors:  Christian Heidbreder
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-10-28       Impact factor: 3.000

5.  The relationship between subcortical brain volume and striatal dopamine D2/3 receptor availability in healthy humans assessed with [11 C]-raclopride and [11 C]-(+)-PHNO PET.

Authors:  Fernando Caravaggio; Jun Ku Chung; Eric Plitman; Isabelle Boileau; Philip Gerretsen; Julia Kim; Yusuke Iwata; Raihaan Patel; M Mallar Chakravarty; Gary Remington; Ariel Graff-Guerrero
Journal:  Hum Brain Mapp       Date:  2017-07-28       Impact factor: 5.038

6.  Stress-induced dopamine response in subjects at clinical high risk for schizophrenia with and without concurrent cannabis use.

Authors:  Romina Mizrahi; Miran Kenk; Ivonne Suridjan; Isabelle Boileau; Tony P George; Kwame McKenzie; Alan A Wilson; Sylvain Houle; Pablo Rusjan
Journal:  Neuropsychopharmacology       Date:  2013-12-24       Impact factor: 7.853

7.  Ventral striatum binding of a dopamine D2/3 receptor agonist but not antagonist predicts normal body mass index.

Authors:  Fernando Caravaggio; Sofia Raitsin; Philip Gerretsen; Shinichiro Nakajima; Alan Wilson; Ariel Graff-Guerrero
Journal:  Biol Psychiatry       Date:  2013-03-27       Impact factor: 13.382

8.  Dopamine response to psychosocial stress in chronic cannabis users: a PET study with [11C]-+-PHNO.

Authors:  Romina Mizrahi; Ivonne Suridjan; Miran Kenk; Tony P George; Alan Wilson; Sylvain Houle; Pablo Rusjan
Journal:  Neuropsychopharmacology       Date:  2012-11-08       Impact factor: 7.853

9.  Parametric Imaging and Test-Retest Variability of ¹¹C-(+)-PHNO Binding to D₂/D₃ Dopamine Receptors in Humans on the High-Resolution Research Tomograph PET Scanner.

Authors:  Jean-Dominique Gallezot; Ming-Qiang Zheng; Keunpoong Lim; Shu-fei Lin; David Labaree; David Matuskey; Yiyun Huang; Yu-Shin Ding; Richard E Carson; Robert T Malison
Journal:  J Nucl Med       Date:  2014-04-14       Impact factor: 10.057

Review 10.  Recent methods for measuring dopamine D3 receptor occupancy in vivo: importance for drug development.

Authors:  Bernard Le Foll; Alan A Wilson; Ariel Graff; Isabelle Boileau; Patricia Di Ciano
Journal:  Front Pharmacol       Date:  2014-07-10       Impact factor: 5.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.